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ABSTRACT
Objective To examine the relation between plasma HIV-1
RNA concentrations in the community and HIV incidence
among injecting drug users.
Design Prospective cohort study.
Setting Inner city community in Vancouver, Canada.
Participants Injecting drug users, with and without HIV,
followedupeverysixmonthsbetween1May1996and30
June 2007.
Main outcome measures Estimated community plasma
HIV-1 RNA in the six months before each HIV negative
participant’s follow-up visit. Associated HIV incidence.
Results Among 622 injecting drug users with HIV, 12435
measurements of plasma HIV-1 RNA were obtained.
Among 1429 injecting drug users without HIV, there were
155 HIV seroconversions, resulting in an incidence
densityof2.49(95%confidenceinterval2.09to2.88)per
100personyears.InaCoxmodelthatadjustedforunsafe
sexual behaviours and sharing used syringes, the
estimated community plasma HIV-1 RNA concentration
remained independently associated with the time to HIV
seroconversion(hazardratio3.32(1.82to6.08,P<0.001),
per log10 increase). When the follow-up period was
limited to observations after 1 January 1988 (when the
median plasma HIV RNA concentration was <20000
copies/ml), the median viral load was no longer
statistically associated with HIV incidence (1.70 (0.79 to
3.67, P=0.175), per log10 increase).
Conclusions A longitudinal measure of community
plasma HIV-1 RNA concentration was correlated with the
community HIV incidence rate and predicted HIV
incidence independent of unsafe sexual behaviours and
sharing used syringes. If these findings are confirmed,
they could help to inform both HIV prevention and
treatment interventions.
INTRODUCTION
Since the mid-1990s, there have been major advances
in the medical management of HIV infection. In parti-
cular, highly active antiretroviral therapy (HAART)
has led to substantial reductions in HIV related mor-
bidity and mortality.
1 As HAART is known to
effectively reduce a patient’s plasma HIV RNA
concentration,
2 it has been debated whether or not
antiretroviral therapy can reduce HIV
transmission.
3-6 While several mathematical models
have suggested this might be the case, researchers
have suggested that the increasing use of HAART
might lead to increased HIV risk behaviour, which
could overwhelm the possible protective effect of
HAART.
3-6 Empirical data are urgently needed to
inform this controversy, particularly given the recent
negative results of clinical trials involving leading can-
didates in the microbicide and vaccine specialties.
78
Thetopichasbeenafocusofrecentacademicmeetings
of HIV experts,
9 and the World Health Organization
recentlyreleasedaconsensusstatementinwhichusing
HAART for HIV prevention was identified as a top
policy-relevant research question.
10
To date, no study has described the real world rela-
tion between community plasma HIV RNA concen-
trations and HIV incidence. This is an important gap
in knowledge because the potential of HAART to
reduce HIV incidence has attracted growing inter-
national interest,
5611 and the ongoing debates over
the possible impact of increasing access to HAART
might be hindering global efforts to increase its
use.
612We therefore tested the hypothesis that a long-
itudinal estimate of community plasma HIV-1 RNA
concentration would be associated with an estimate of
community HIV incidence independent of HIV risk
behaviours, such as sharing used syringes and enga-
ging in unsafe sexual practices.
DESIGN
Between 1 May 1996 and 30 June 2007, injecting drug
users with and without HIV were recruited into a pro-
spective cohort study from the Downtown Eastside
neighbourhood of Vancouver, Canada. Individuals
were recruited regardless of HIV status and followed
upeverysixmonths.Twovirtualcohortswere created
at the databaselevel to independently assess incidence
of HIV and plasma viral load. Those without HIV at
baselinemadeuptheVancouverInjectionDrugUsers
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ingdrugusersdescribedindetailpreviously.
1314Those
withHIV-1madeupanothercohortknownastheBar-
riers to Accessing Antiretroviral Therapy (BART).
1516
Briefly,atbaselineparticipantsgavebloodsamplesfor
HIVserologyandcompletedaquestionnaireadminis-
tered by an interviewer and then returned every six
months for follow-up evaluation. Extensive outreach
methods with snowball sampling techniques
1718 were
used to derive a representative sample. Individuals
who agreed to participate were offered $C20 at each
study visit. Because of the extent of poverty in the
neighbourhood,aswellasthenursingandsupportser-
vices offered through the study, the estimated refusal
rate for participation in the study was under 10%.
19
Community plasma HIV-1 RNA concentrations
We estimated community plasma HIV-1 RNA con-
centrations every six months using data from BART
cohort participants recruited from 1 May 1996 to 30
June 2007. Plasma HIV-1 RNA concentration was
measured with the Roche Amplicor Monitor assay
(Roche Molecular Systems, Mississauga, Canada). All
plasma HIV-1 RNA samples collected from BART
participantsat follow-upwere used to derive a longitu-
dinal estimate of the plasma HIV-1 RNA concentra-
tion in the community over time. As previously
described,
1516 the local setting is quite unusual in that
there is a centralised antiretroviral dispensation pro-
gramme and HIV/AIDS laboratory, allowing for a
complete prospective profile of plasma HIV-1 RNA
levels and use of antiretroviral therapy among cohort
participants.
In addition, to determine explanations for changing
concentrations of community plasma HIV-1 RNA
during follow-up, we assessed use of antiretrovirals
among BART participants during each year of the
study and analysed changes during the study period
using the Mantel test for trend.
Community HIV-1 incidence
Weusedsimilarstandardisedfollow-upmethodsevery
six months (that is, twice a year) to estimate the annual
HIV incidence among participants recruited into the
VIDUS cohort. As previously described,
14 HIV infec-
tionwasassessedateachfollow-upvisit,andthedateof
HIV seroconversion was estimated with the midpoint
between the last negative and the first positive anti-
body test result. We considered all participants with
at least one follow-up visit to determine HIV inci-
dence, and participants who remained persistently
HIV seronegative were censored at the time of their
most recent HIV antibody test result before 30 June
2007. HIV tests reactive on enzyme linked immuno-
sorbent assay at St Paul’s Hospital were confirmed by
western blotting at the British Columbia Centre for
Disease Control.
Statistical analyses
To assess for a possible crude correlation between the
twice a year estimates of community plasma HIV-1
RNA and the twice a year estimates of community
HIV incidence, we first divided the study period into
six month intervals and usedthe Spearmanrank order
correlation coefficient to assess for statistical correla-
tion. In addition, to present the data visually, we also
plotted the median plasma HIV RNA concentrations
and the incidence density every six months for each
yearofthestudyandpresentedtheuncertaintyaround
these estimates by calculating 95% confidence inter
vals.
20 For the estimates of HIV incidence, we calcu-
lated95%confidenceintervalsusingthePoissondistri-
bution.FortheestimatesofmedianplasmaHIV-RNA
concentration,wecalculatednon-parametrictwosided
95% confidence intervals by non-parametric methods
based on the ordered plasma HIV-1 RNA concentra-
tions.
We also used Cox proportional hazards regression
to assess factors associated with the time to HIV infec-
tion and examined whether the estimated community
plasma HIV-1 RNA concentration in the six months
beforeeachparticipant’sfollow-upvisitwasassociated
with HIV-1 incidence, while adjusting for HIV risk
behaviour. Specifically, to assess for potential con-
founding, we calculated unadjusted and adjusted
hazard ratios of HIV infection per log10 increase in
theestimatedcommunityplasmaHIV-1RNAconcen-
tration. The multivariate model was fitted with an a
priori defined modelling approach whereby we exam-
ined the hazard ratio for HIV-1 RNA after adjustment
for HIV risk behaviours and previously identified
potential confounders. Specifically, we adjusted for
sharingusedsyringes(yesversusno),unsafesex(inser-
tive or receptive anal or vaginal intercourse without a
condom versus no unsafe sex), ethnicity (white versus
other), cocaine use (≥ daily versus < daily), heroin use
(≥dailyversus<daily),andunstablehousing(livingin
a single room occupancy hotel, shelter, recovery or
transition house, jail, on the street, or having no fixed
addressversushavingstablehousing).Aswiththeesti-
matedcommunityplasmaHIV-1RNAconcentration,
all behavioural variables were time updated based on
the data of the twice a year questionnaire and refer to
the six months before the interview. All behavioural
Year
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Median plasma HIV RNA concentration
HIV incidence density
Estimated community plasma HIV-1 RNA concentrations and HIV incidence density, with 95%
confidence intervals, among two parallel cohorts of injecting drug users. HIV incidence first
estimated in second half of 1996 as enrolment started in May 1996 and repeat HIV tests to
assess incidence were available only after six months of follow-up
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1314 To assess for explanations for changes in
plasmaHIVRNAconcentrationsovertime,welinked
participants to the local province-wide antiretroviral
dispensation programme to examine patterns of anti-
retroviral use during the study period. Analyses were
conducted with SAS 9.1 (Cary, NC) and the threshold
forsignificancewassetatP<0.05.AllPvaluesweretwo
sided.
RESULTS
Table 1 shows the baseline characteristics of the
cohorts of participants with and without HIV. The
baseline age was similar between the two cohorts
(36.6 v 36.1 years), whereas those with HIV were
more likely to be female (250 (40.2%) v 464 (32.5%))
andofnon-whiteethnicity(270(43.4%)v530(37.1%)).
Community plasma HIV-1 RNA
During the study period, 622 BART participants
underwent plasma HIV-1 RNA assessments, among
whom 250 (40.2%) were women and the median age
was37(interquartilerange30-43).Amongthe622par-
ticipants, there were 12435 plasma HIV-1 RNA
assessments,with a median of 17 (8-31) measurements
per person. The figure shows the estimated median
plasma HIV-1 RNA concentrations every six months
for 1996-2007.
HIV-1 incidence
During the study period, 1796 individuals who were
HIV negative at baseline were enrolled into the
VIDUS cohort. Of these, 367 (20.4%) were lost to fol-
low-upbeforere-assessmentofHIVinfectionandwere
thereforeexcluded from furtheranalysis. Those lost to
follow-up were more likely to be white (P=0.012), but
there were no age or sex differences (both P>0.05).
Among the 1429 individuals included in the HIV inci-
dence analyses, 464 (32.5%) were women, the median
age was 36.1 (27.2-42.4), and the median number of
follow-up visits was 8 (3-16). During the study period,
there were 155 HIV seroconversions, resulting in an
overall incidence density of 2.49 (95% confidence
interval 2.09 to 2.88) per 100 person years. The figure
shows the incidence density for every six months for
1996-2007.
HIV-1 RNA and HIV incidence
As implied by the patterns in the figure, when we
divided the 11 year study period into 22 six month
intervals, the median plasma HIV-1 RNA concentra-
tion and the HIV-1 incidence were correlated (Spear-
man correlation coefficient 0.48; P=0.024).
In unadjusted Cox regression analyses, we found
that the median estimated community plasma HIV-1
RNAconcentrationduringthesix monthsbeforeeach
HIV negative participant’s follow-up visit was asso-
ciated with HIV seroconversion (hazard ratio 3.57
(2.03 to 6.27), P<0.001, per log10 increase). As shown
in table 2, in a multivariate model that adjusted for
sharing used syringes, unsafe sex, ethnicity, daily
cocaine use, daily heroin use, and unstable housing,
the median plasma HIV-1 RNA concentration during
the six months before each HIV negative participant’s
follow-up visit remained independently associated
with the time to HIV seroconversion (hazard ratio
3.32 (1.82 to 6.08), P<0.001, per log10 increase). In a
post-hoc analysis, which limited follow-up to the per-
iod after 1 January 1988 (when the median plasma
HIV RNA concentration was <20000 copies/ml), we
found that the median viral load was no longer signifi-
cantly associated with HIV incidence (1.70 (0.79 to
3.67), P=0.175, per log10 increase).
Whenwe assessedfor explanations forthe observed
longitudinal pattern of estimated community plasma
HIV-1RNA(figure),wefoundthatthenumberofindi-
viduals who had started antiretroviral therapy
increased during the study period from 42.5% in
1996 to 69.6% in 2007 (Mantel test for trend across all
11 years P<0.001). Among those receiving anti-
retroviral drugs, we found that the number using at
least three antiretroviral drugs (versus fewer than
three drugs) in their antiretroviral regimen increased
during the study period from 8.4% in 1996 to 98.8%
in 2007 (Mantel test for trend across all 11 years
P<0.001).
DISCUSSION
In a small urban neighbourhood with high rates of
injectingdruguse,wefoundthatestimatedcommunity
Table 1 |Baseline demographic characteristics of injecting
drug users with and without HIV. Figures are numbers
(percentages) of participants unless stated otherwise
Characteristic
HIV positive*
(n=622)
HIV negative†
(n=1429)
Median (IQR) age
(years)
36.6 (30.3-43.3) 36.1 (27.2-42.4)
Male 372 (59.8) 965 (67.5)
Female 250 (40.2) 464 (32.5)
Ethnicity:
White 352 (56.6) 899 (62.9)
Other 270 (43.4) 530 (37.1)
IQR=interquartile range.
*Cohort used to estimate longitudinal pattern of plasma viral load.
†Cohort used to evaluate HIV incidence in community.
Table 2 |Cox proportional hazards regression of time to HIV infection among 1429 HIV
negative injecting drug users followed from 1 May 1996 to 30 June 2007
Characteristic Relative hazard (95% CI) P value
Plasma HIV RNA (per log10 increase)* 3.32 (1.82 to 6.08) <0.001
Unsafe sex† (yes v no)‡ 1.09 (0.77 to 1.54) 0.619
Used syringe sharing (yes v no) 1.45 (0.99 to 2.12) 0.058
Ethnicity (white v other) 0.65 (0.47 to 0.91) 0.011
Heroin injection (≥daily v <daily)‡ 1.35 (0.97 to 1.90) 0.079
Cocaine injection (≥daily v <d a i l y ) ‡ 2.50 (1.76 to 3.54) <0.001
Unstable housing (yes v no)§ 1.41 (1.00 to 1.98) 0.049
*Plasma HIV RNA was time updated based on median value in BART cohort during six months before each HIV
negative participant’s follow-up visits.
†Defined as insertive or receptive vaginal or anal intercourse.
‡All behavioural data time updated based on data from follow-up every six months.
§Living in single room occupancy hotel, shelter, recovery or transition house, jail, on street, or having no fixed
address.
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mated community HIV incidence, and that this asso-
ciation was independent of HIV risk behaviours and
other potential confounders. Previous studies have
suggested that injecting drug users might be less likely
to access antiretroviral therapy because of physicians’
concerns related to lifestyle issues and reduced anti-
retroviral adherence.
21 If our findings are confirmed,
outreach strategies could be used to improve access
to HAART among this population in an effort to
reduce the HIV incidence. Any benefit of earlier use
of HAART, however, must be balanced with anti-
retroviral toxicities and potential for increased anti-
retroviral resistance.
22
Comparison with other studies
Our study was observational, and the observed
declines in HIV incidence in the community might
not be causally related to the observed decline in the
estimated community plasma viral load. It is nonethe-
less compelling that the effect of plasma HIV-1 RNA
on HIV incidence was independent of time updated
measurements of HIV risk behaviours, drug use pat-
terns, and other possible confounders. Several lines of
evidence support the hypothesis that community
plasma HIV-1 RNA concentrations might be among
the factors that determine community HIV incidence.
Most importantly, HAART has been shown to reduce
HIV-1RNAconcentrationsinblood,
23thefemalegen-
ital tract,
24 the rectum,
25 and semen,
26 which might
make those with HIV less likely to transmit the
virus.
5 An ecological study from Taiwan showed that
the expanded use of HAART was associated with a
greater than 50% reduction in new HIV cases.
27 Simi-
larly, a study from Uganda, which examined couples
serodiscordant for HIV, found no cases of HIV trans-
missionwheretheindexcasehadanHIV-1RNAcon-
centration below 1500 copies/ml.
28 Interestingly, we
found that the association between plasma viral load
and HIV incidence was no longer significant in suba-
nalyses restricted to the period when the median viral
load reached <20000 copies/ml. This finding intro-
duces some uncertainty into our overall finding as it
suggests that our results are largely driven by the
early years, during which the plasma viral load was
high. The relation between viral load and HIV inci-
dence might be less strong when viral load is below a
certain threshold. Alternatively, as this is an observa-
tional study, an unmeasured confounding variable
might explain the association, and the results in this
subanalysis might not have been consistent because
this confounding variable did not have a consistent
effect throughout the follow-up period.
Strengths and limitations
Ouranalyseswerealsolimitedbythefactthatthereisa
known delay between HIV exposure and seroconver-
sions, and, consistent with most studies on HIV inci-
dence, we had to estimate an individual’s date of HIV
seroconversion as the midpoint between the last nega-
tive HIV test and the first positive test.
14 As a result,
HIV seroconversions might have happened slightly
earlier than the year to which they were assigned in
our study. Regarding this limitation, it is interesting
that the highest rate of HIV seroconversion was
observed in the year after the highest community
plasma HIV-1 RNA concentration. Antiretroviral
resistance is unlikely to explain our findings as
increasedresistanceisassociatedwithuseoflesspotent
antiretrovirals and increasing viral load,
2930 whereas
during the study period we observed the use of more
potent antiretroviral therapy and decreased plasma
HIV RNA concentrations. Finally, although we used
extensive outreach methods and snowball sampling
techniques in an effort to derive a representative
sample,
1718 injecting drug users are a highly margina-
lised and hiddenpopulation,and we do notknow with
certainty that our cohort is representative of injecting
drug users in the community. Previous studies have
suggested the demographics of our cohort are consis-
tent with other samples of the city’s injecting drug
users,
31 and it is noteworthy that our study encom-
passes about 30% of the estimated 4700 injecting
drug users living in the neighbourhood (unpublished
report, Health Canada, 1998). Although the question
of the impact of a community’s plasma HIV-1 RNA
concentration on HIV incidence might be better
answered by a study design that randomised commu-
nities to differing levels of HAART use, such an
approach might present ethical challenges because of
HAART’s known effects on reducing mortality, and
these data are not presently available.
Conclusions and policy implications
Wehaveshownthatalongitudinalmeasureofcommu-
nityplasmaHIV-1RNAconcentrationcorrelateswith
the community HIV incidence rate and can predict
HIV incidence independent of unsafe sexual beha-
vioursandsharingsyringes.Thesedatashouldprompt
a re-examination of arguments that dichotomise HIV
prevention and HIV treatment, as they might not be
independent strategies to reduce the rate of new HIV
infections.
612Thesedatashouldalsohelptoinformthe
debates regarding global increase in use of anti-
retrovirals and possible unintended negative impacts
of expanded HAART use on HIV risk behaviour and
new HIV infections, as expanded HAART use in the
communitywasassociatedwithbothreducedcommu-
nityplasmaHIVRNA concentrationsandsubsequent
HIV incidence.
3-6
We thank the VIDUS and BART participants, and Deborah Graham, Tricia
Collingham, and Kelly Hsu for their research and administrative
assistance.
Contributors: EW designed the study, wrote the initial draft of the
manuscript, and is guarantor. RZ and KL conducted the statistical
analyses. All authors contributed to the design of the study and the
drafting of the manuscript.
Funding: The VIDUS and BART studies are supported by US National
Institutes of Health grants R01DA011591 and R01DA021525 and by
Canadian Institutes of Health Research grant MOP-79297. TK is
supported by a Canadian Institutes of Health Research (CIHR) new
investigator award and a Michael Smith Foundation for Health Research
(MSFHR)scholaraward.BDLMissupportedbyadoctoralresearchaward
from CIHR and a MSFHR senior trainee award. JSGM has received an
RESEARCH
page 4 of 5 BMJ | ONLINE FIRST | bmj.comAvant-Garde award (DP1 DA026182) from the National Institute of Drug
Abuse,NationalInstitutesofHealth.Theauthorsaffirmtheindependence
of the researchers from the funders.
Competing interests: RSH has received funding for research and
continuing medical education programmes from pharmaceutical
companies, including Abbott, Boehringer Ingelheim, and
GlaxoSmithKline. JSGM has received educational grants from, served as
an ad hoc adviser to, or spoken at various events sponsored by Abbott
Laboratories, Agouron Pharmaceuticals, Boehringer Ingelheim
Pharmaceuticals, Borean Pharma AS, Bristol-Myers Squibb, DuPont
Pharma, Gilead Sciences, GlaxoSmithKline, Hoffmann-La Roche, Immune
Response Corporation, Incyte, Janssen-Ortho, Kucera Pharmaceutical
Company, Merck Frosst Laboratories, Pfizer Canada, Sanofi Pasteur,
Shire Biochem, Tibotec Pharmaceuticals, and Trimeris.
Ethical approval: The research was approved by the University of British
Columbia’s research ethics board at St Paul’s Hospital.
1 Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J,
Satten GA, et al. Declining morbidity and mortality among patients
with advanced human immunodeficiency virus infection. HIV
Outpatient Study Investigators. NE n g lJM e d1998;338:853-60.
2 Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM,
Currier JS, et al. A controlled trial of two nucleoside analogues plus
indinavir in persons with human immunodeficiency virus infection
and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical
Trials Group 320 Study Team. NE n g lJM e d1997;337:725-33.
3 BlowerSM,GershengornHB,GrantRM.Ataleoftwofutures:HIVand
antiretroviral therapy in San Francisco. Science 2000;287:650-4.
4 Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could
widespread use of combination antiretroviral therapy eradicate HIV
epidemics? Lancet Infect Dis 2002;2:487-93.
5 Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review:
antiretroviral therapy to prevent the sexual transmission of HIV-1.
A n nI n t e r nM e d2007;146:591-601.
6 Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The
case for expanding access to highly active antiretroviral therapy to
curb the growth of the HIV epidemic. Lancet 2006;368:531-6.
7 HIV vaccine failure prompts Merck to halt trial. Nature
2007;449:390.
8 Cohen J. AIDS research. Microbicide fails to protect against HIV.
Science 2008;319:1026-7.
9 Steinbrook R. The AIDS epidemic—a progress report from Mexico
City. NE n g lJM e d2008;359:885-7.
10 World Health Organization. Consensus statement: addressing
knowledge gaps in the public health approach to delivering
antiretroviral therapy and care. www.iasociety.org/Web/
WebContent/File/Consensus%20Statement%2030-07-08.pdf.
1 1 A c e i j a sC ,O p p e n h e i m e rE ,S t i m s o nG V ,A s h c r o f tR E ,M a t i cS ,
Hickman M. Antiretroviral treatment for injecting drug users in
developing and transitional countries 1 year before the end of the
“Treating 3 million by 2005. Making it happen. The WHO strategy”(“3
by 5”). Addiction 2006;101:1246-53.
12 Marseille E, Hofmann PB, Kahn JG. HIV prevention before HAART in
sub-Saharan Africa. Lancet 2002;359:1851-6.
13 Kerr T, Tyndall M, Li K, Montaner JS, Wood E. Safer injection facility
use and syringe sharing in injection drug users. Lancet
2005;366:316-8.
14 Wood E, Lloyd-Smith E, Li K, Strathdee SA, Small W, Tyndall MW,
etal.FrequentneedleexchangeuseandHIVincidenceinVancouver,
Canada. Am J Med 2007;120:172-9.
15 Strathdee SA, Palepu A, Cornelisse PG, Yip B, O’Shaughnessy MV,
Montaner JS, et al. Barriers to use of free antiretroviral therapy in
injection drug users. JAMA 1998;280:547-9.
16 Wood E, Hogg RS, Bonner S, Kerr T, Li K, Palepu A, et al. Staging for
antiretroviral therapy among HIV-infected drug users. JAMA
2004;292:1175-7.
17 Dunn J, Ferri CP. Epidemiological methods for research with drug
misusers: review of methods for studying prevalence and morbidity.
Rev Saude Publica 1999;33:206-15.
18 Lopes CS, Rodrigues LC, Sichieri R. The lack of selection bias in a
snowball sampled case-control study on drug abuse. Int J Epidemiol
1996;25:1267-70.
19 Strathdee SA, Patrick DM, Currie SL, Cornelisse PG, Rekart ML,
Montaner JS, et al. Needle exchange is not enough: lessons from the
Vancouver injecting drug use study. AIDS 1997;11:F59-65.
20 Collett, D. Modelling survival data in medical research.N e wY o r k :
Chapman & Hall, 1994.
21 Loughlin A, Metsch L, Gardner L, Anderson-Mahoney P, Barrigan M,
Strathdee S. Provider barriers to prescribing HAART to medically-
eligible HIV-infected drug users. AIDS Care 2004;16:485-500.
22 Wood E, Hogg RS, Harrigan PR, Montaner JS. When to initiate
antiretroviral therapy in HIV-1-infected adults: a review for clinicians
and patients. Lancet Infect Dis 2005;5:407-14.
23 Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS. Impact
of baseline viral load and adherence on survival of HIV-infected
adults with baseline CD4 cell counts > or =200 cells/microl. AIDS
2006;20:1117-23.
24 Cu-Uvin S, Caliendo AM, Reinert S, Chang A, Juliano-Remollino C,
Flanigan TP, et al. Effect of highly active antiretroviral therapy on
cervicovaginal HIV-1 RNA. AIDS 2000;14:415-21.
2 5 L a m p i n e nT M ,C r i t c h l o wC W ,K u y p e r sJ M ,H u r tC S ,N e l s o nP J ,
Hawes SE, et al. Association of antiretroviral therapy with detection
of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men.
AIDS 2000;14:F69-75.
26 Vernazza PL, Gilliam BL, Flepp M, Dyer JR, Frank AC, Fiscus SA, et al.
Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS
1997;11:1249-54.
27 Fang CT, Hsu HM, Twu SJ, Chen MY, Chang YY, Hwang JS, et al.
Decreased HIV transmission after a policy of providing free access to
highly active antiretroviral therapy in Taiwan. JI n f e c tD i s
2004;190:879-85.
28 Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C,
Wabwire-Mangen F, et al. Viral load and heterosexual transmission
ofhumanimmunodeficiencyvirustype1.RakaiProjectStudyGroup.
NE n g lJM e d2000;342:921-9.
29 Martinez-Picado J, DePasquale MP, Kartsonis N, Hanna GJ, Wong J,
Finzi D, et al. Antiretroviral resistance during successful therapy of
HIV type 1 infection. Proc Natl Acad Sci U S A 2000;97:10948-53.
30 Gallego O, de Mendoza C, Perez-Elias MJ, Guardiola JM, Pedreira J,
Dalmau D, et al. Drug resistance in patients experiencing early
virological failure under a triple combination including indinavir.
AIDS 2001;15(13):1701-6.
31 Tyndall MW, Craib KJ, Currie S, Li K, O’Shaughnessy MV,
Schechter MT. Impact of HIV infection on mortality in a cohort of
injection drug users. J Acquir Immune Defic Syndr 2001;28:351-7.
Accepted: 12 January 2009
WHAT IS ALREADY KNOWN ON THIS TOPIC
Antiretroviral therapy reduces plasma viral load and reduces HIV related mortality
Its potential role in reducing HIV transmission by reducing an individual’s infectivity is
controversial
Drug misusers with HIV are less likely to access HAART (highly active antiretroviral therapy)
than other people with HIV
WHAT THIS STUDY ADDS
A longitudinal measure of community plasma HIV-1 RNA correlates with the community HIV
incidence rate and predicts HIV incidence independent of unsafe sexual behaviours and
sharing syringes
These data should prompt a re-examination of arguments that dichotomise HIV prevention
and HIV treatment, which might not be independent strategies for reducing the rate of new
HIV infections
Injecting drug users can be successfully attracted to and retained in HAART programmes
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